Regenxbio (NASDAQ: RGNX) — Perfil da empresa, notícias e dados financeiros
Regenxbio focuses on gene therapy development through its NAV technology platform, aiming to address serious diseases with transformative treatments.
Regenxbio
Regenxbio (NASDAQ:RGNX) is a biotechnology company focused on the development, commercialization, and licensing of its proprietary NAV technology platform for gene therapy. Its operations are dedicated to discovering and developing therapeutics to improve the lives of patients suffering from serious diseases, including genetic disorders, metabolic diseases, and retinal diseases. Through its versatile NAV technology platform, Regenxbio is advancing a diverse pipeline of gene therapy candidates with the aim of addressing unmet medical needs. The company's objectives center around leveraging its leading technology platform to create transformative gene therapies that can offer long-lasting effects and improve patient health outcomes. In pursuit of these goals, Regenxbio actively engages in research and development, clinical trials, and strategic collaborations to expand its portfolio and enhance the potential of gene therapy applications.
Resumo
Operações
Produtos e/ou serviços de Regenxbio
- RGX-314 for wet age-related macular degeneration and diabetic retinopathy, a gene therapy delivered through subretinal injection.
- NAV Technology Platform, a suite of adeno-associated virus (AAV) vectors for gene therapy applications.
- RGX-121 for Mucopolysaccharidosis Type II (MPS II), designed to deliver the IDS gene directly to the central nervous system.
- RGX-111 for Mucopolysaccharidosis Type I (MPS I), targeting the delivery of the IDUA gene to the brain via direct administration.
- RGX-202 for Duchenne Muscular Dystrophy, a gene therapy aiming at restoring dystrophin protein levels.
- RGX-501 for Homozygous Familial Hypercholesterolemia, a gene therapy intended to correct the LDL receptor gene defect.
equipe executiva do Regenxbio
- Curran M. SimpsonPresident, CEO & Director
- Patrick J. Christmas IIExecutive VP & Chief Strategy and Legal Officer
- Stephen PakolaExecutive VP & Chief Medical Officer
- Mitchell ChanExecutive VP & CFO
- Craig MalzahnExecutive VP of Product Development & CTO
- Olivier DanosExecutive VP & Chief Scientific Officer
- Ram PalankiExecutive VP & Chief Commercial Officer
- Jahannaz DastgirClinical Development Lead
Últimas notícias sobre a Regenxbio
REGENXBIO reports three-year ALTITUDE results for sura-vec diabetic retinopathy program
United StatesREGENXBIO pauses RGX-121 FDA review
United StatesREGENXBIO doses first patient in DR trial
United StatesREGENXBIO completes RGX-202 dosing in confirmatory study
United StatesREGENXBIO targets Q3 for gene therapy resubmission
United StatesREGENXBIO swings to Q1 loss, but pivotal Duchenne gene therapy data eyes 2027 launch
United States
Principais indicadores financeiros
Resultados divulgados pela Regenxbio, em USD.
- Cap. de mercado
- 435,7 mi
- Receita (TTM)
- 174,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.8
- Dividend yield
- —
- Margem de lucro
- -112.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 170,4 mi | -161,2 mi | -193,9 mi | |
| 83,3 mi | -233,3 mi | -227,1 mi | |
| 90,2 mi | -268,1 mi | -263,5 mi | |
| 112,7 mi | -262,9 mi | -280,3 mi |